Introduction Disruptions of proteasome and autophagy systems are central events in
amyotrophic lateral sclerosis (ALS) and support the urgent need to find therapeutic compounds …

In preclinical studies rapamycin was found to target neuroinflammation, by expanding
regulatory T cells, and affecting autophagy, two pillars of amyotrophic lateral sclerosis (ALS) …

Methods: RAP-ALS is a phase II randomized, double-blind, placebo-controlled, multicenter (8
ALS centers in Italy), clinical trial. The primary aim is to assess whether Rapamycin …

Motor neuron diseases (MNDs) are etiologically and biologically heterogeneous diseases.
The pathobiology of motor neuron degeneration is still largely unknown, and no effective …

Background Amyotrophic lateral sclerosis (ALS) is known to represent a collection of overlapping
syndromes. Various classification systems based on empirical observations have been …

Objectives: Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative
disease with still unknown etiology. We aimed at investigating the association between …

The historical view that Amyotrophic Lateral Sclerosis (ALS) as a pure motor disorder has
been increasingly challenged by the discovery of cognitive and behavioral changes in the …

Background and purpose Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective …

Background and Rationale: Among the key players in the pathogenesis of Amyotrophic
Lateral Sclerosis (ALS), microglia and T regulatory lymphocytes (Treg) are candidate cells for …

Background: Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative
disease of the motor neurons. The etiology of ALS remains largely unknown, particularly with …